CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure) Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Dapagliflozin for treating chronic heart failure with reduced ejection fraction The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Clinical TrialNovember 10, 2018

JOURNAL:N Engl J Med. Article Link

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

SD Wiviott,I Raz,DECLARE–TIMI 58 Investigators. Keywords: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Hypertension, Smoking

FULL TEXT PDF